Masaaki Inaba — Page 8

PubMed2002

[Clinical usefulness serum int-P I NP levels as a bone formation marker in hemodialysis patients].

Since intact collagen I amino-terminal propeptide (P I NP) is known to be cleared from blood via liver, its level in blood is hypothesized to be independent of renal function. Serum P I NP, in contrast to serum bone alkaline phosphatase (BAP) and intact osteocalcin (OC), did not show any significant change between before and after a hemodialysis session. Serum P I NP correlated significantly in a positive manner with the other bone formation markers, bone-specific alkaline phosphatase and osteocalcin and also with intact parathyroid hormone in the patients on hemodialysis. In summary, serum P I NP may be very useful for prediction of radius bone loss as well as other serum bone formation markers and evaluating the osteoblastic function in hemodialyzed patients.

English Abstract↗

PubMed2001

Increasing body fat mass in the first year of hemodialysis.

Nutritional status affects well-being and survival in patients who are undergoing hemodialysis. It was examined how maintenance hemodialysis altered body fat mass. In 72 patients with chronic renal failure (age, 62 +/- 12 yr; 42 men, 30 women), body fat was measured by dual x-ray absorptiometry 1 mo after initiation of maintenance hemodialysis and approximately 1 yr later (mean +/- SD, 11 +/- 2 mo). The second measurement showed significantly greater body fat mass than the first (11.38 +/- 3.84 versus 10.09 +/- 4.12 kg; P < 0.0001). After calculation of the change in body fat mass per month, no significant differences were evident in relation to gender or to presence of diabetes. Changes in body fat mass per month correlated negatively with baseline serum albumin concentration (r = -0.449, P < 0.0001) and baseline body fat mass (r = -0.423, P < 0.001). These factors independently influenced the change according to multiple regression analysis (R(2) = 0.323, P < 0.0001). In conclusion, body fat mass increases significantly in the first year of maintenance hemodialysis, especially in patients with poor nutritional status. More general, dual x-ray absorptiometry assessment of body fat mass was found to be useful for evaluating the nutritional status of hemodialysis patients.

Absorptiometry, Photon↗

PubMedDate not supplied

How to eradicate Helicobacter pylori using amoxicillin and omeprazole in the remnant stomach.

BACKGROUND/AIMS: We previously investigated the effects of amoxicillin/omeprazole combined therapy on patients who were Helicobacter pylori (H. pylori) positive after gastrectomy for the treatment of gastric cancer, and we determined the difference in amoxicillin dosage between the therapeutic successes and failures. In the present study, assuming that amoxicillin dosage should be determined on the basis of body weight of each patient, we examined whether the eradication of H. pylori would be improved by using this novel dose-selection method. METHODOLOGY: We have previously reported about eradication of H. pylori of remnant stomach as follows. Patients who underwent gastrectomy for the treatment of gastric cancer were enrolled if H. pylori was detected in their remnant stomach after the operation. Of these patients, 22 were treated with amoxicillin at 750 mg/day for 2 weeks and omeprazole at 20 mg/day for 8 weeks. For the evaluation of H. pylori eradication, endoscopic examination and 13C-urea breath test were performed 12 weeks after the initiation of the treatment. The amoxicillin dosage in the therapeutic successes was compared with that in the therapeutic failures, and we found that the dosage was 14.1 +/- 1.5 and 12.5 +/- 1.5 mg/kg/day in the successes and the failures, respectively. Following these results, another 10 H. pylori-positive patients were treated with amoxicillin greater than 16 mg/kg/day for 2 weeks and omeprazole at 20 mg/day for 8 weeks, and H. pylori eradication was evaluated as mentioned above. The efficacy of the drug therapy on H. pylori infection was compared between the two groups that one group (Group A) is treated with amoxicillin 750 mg/day for 2 weeks and omeprazole at 20 mg/day for 8 weeks and the other group (Group B) is treated with 1250 mg/day for 2 weeks and omeprazole at 20 mg/day for 8 weeks. RESULTS: The eradication rate of H. pylori in Group B (84.6%) was higher than that in Group A (42.1%). There was significant difference between the two groups (p = 0.028). CONCLUSIONS: We assumed that the optimal dosage of amoxicillin was over 15.6 mg/kg/day for omeprazole-amoxicillin combined therapy for gastrectomized patients who were H. pylori positive, and the favorable therapeutic effects could be obtained by applying this amoxicillin dosage to the eradication of H. pylori.

Amoxicillin↗